Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Reform Bill Would Give Commissioner Fixed Term, Add Review Board

This article was originally published in The Tan Sheet

Executive Summary

The Transforming the Regulatory Environment to Accelerate Access to Treatments Act would mandate a fixed six-year term for the FDA commissioner and the agency’s centers would receive a chief medical policy officer, according to a draft of the bill.

You may also be interested in...



FDA's Office of Medical Policy Grows Into A "Super Office"; DDMAC Gets A Promotion

The Office of Medical Policy now houses the Office of Prescription Drug Promotion (formerly DDMAC) and the newly created Office of Medical Policy Initiatives.

What’s In A PDUFA Reauthorization? Maybe These Issues…

BIO’s "Big Ideas" For FDA Reform Are Too Big For PDUFA

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS105479

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel